Britain was the first country to reach an agreement with BioNTech/Pfizer to supply vaccines and has already ordered 30 million doses in July. Since then, it has signed a contract for an additional 10 million doses. 4 million doses are expected to arrive by the end of December. The Department of Health and Social Care confirmed that the company has received compensation that protects it from legal action due to vaccine-related problems. Permission to supply the product is conditional on the above guarantees being correct and the product can be delivered and stored safely throughout the supply chain, in accordance with the above guarantees. Other countries are not far away: the United States and the European Union are also reviewing Pfizer`s shooting along with a similar vaccine from competitor Moderna Inc. British supervisors are also considering a new shooting by AstraZeneca and Oxford University. “It will inevitably take a few months to protect the most vulnerable,” he said, referring to the “immense logistical challenges” of vaccinating vulnerable groups with the two-dose vaccine. This press release contains “forward-looking statements” from BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements may contain information about BioNTech`s efforts to combat COVID-19, but not limited to this: the opening date of clinical trials with BNT162 and the likely publication of data from these clinical trials; The date of authorization or authorization for the use of an emergency physician; The potential for additional supply agreements with other legal systems or the COVAX facility; The potential safety and effectiveness of BNT162; BioNTech and Pfizer`s cooperation in developing a potential COVID-19 vaccine; and BioNTech`s ability to provide quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. All forward-looking statements contained in this press release are based on BioNTech`s current expectations and beliefs in future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and negatively from the results presented or implied in such forward-looking statements. These risks and uncertainties include, among other things, competition for the creation of a vaccine against COVID-19; The ability to achieve comparable clinical outcomes in larger and more diverse clinical trials; The ability to effectively develop our production capacity; and other potential difficulties. An explanation of these risks and other uncertainties can be contained in BioNTech`s Management Report on Form 20-F, submitted to the SEC on March 31, 2020 and available on the SEC`s website at www.sec.gov. All information contained in this press release refers to the date of publication and BioNTech undertakes no commitment to update this information, unless required by law. The agencies responsible for the transit of the product to the designated NHS entities or the manufacturer`s NHS suppliers in the United Kingdom must also meet the licensing requirements applicable to them as the conditions of this authorization. Pfizer and BioNTech have submitted their COVID 19 vaccine to the European Medicines Agency for conditional approval. Companies have already taken similar steps in the United States and the United Kingdom.

Britain officially withdrew from the EU in January, but is still in a transition phase until the end of this year.